ALD1613, A Novel Long-Acting Monoclonal Antibody to Control ACTH-Driven Pharmacology
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Adrenocorticotropic hormone (ACTH) is the primary regulator of adrenal glucocorticoid production. Elevated levels of ACTH play a critical role in disease progression in several indications, including congenital adrenal hyperplasia and Cushing disease. We have generated a specific, high-affinity, neutralizing monoclonal antibody (ALD1613) to ACTH. In vitro, ALD1613 neutralizes ACTH-induced signaling via all 5 melanocortin receptors and inhibited ACTH-induced cyclic adenosine monophosphate accumulation in a mouse adrenal cell line (Y1). ALD1613 administration to wild-type rats significantly reduced plasma corticosterone levels in a dose-dependent manner. In rodent models with either chronic infusion of ACTH or acute restraint stress-induced ACTH, corticosterone levels were significantly reduced by ALD1613. Administration of ALD1613 to nonhuman primates on days 1 and 7 stably reduced plasma cortisol levels >50% for 57 days. ALD1613 demonstrates the potential of a monoclonal antibody to be an effective therapeutic for conditions with elevated ACTH levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pharmacokinetic–pharmacodynamic studies in rodents and cynomolgus monkeys demonstrated substantial and durable reductions in plasma levels of glucocorticoid134.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [134]
In the citing paper
“ALD1613 (Alder BioPharmaceuticals, USA) is a specific, high-affinity, long-acting humanized, neutralizing, monoclonal antibody to ACTH that has been tested in preclinical studies134,135.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress
Tsigos, C., & Chrousos, G. P. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(02)00429-4 · Cited by 2,822
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Restraint stress in biomedical research: A review
Paré, W. P., & Glavin, G. B. (1986) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(86)90017-5 · Cited by 376
Circadian rhythm of adrenal glucocorticoid: its regulation and clinical implications
Chung, S., Son, G. H., & Kim, K. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.02.003 · Cited by 305
Feelders, R. A., Pulgar, S. J., Kempel, A., & Pereira, A. M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1095 · Cited by 256
Melanocortin receptors: their functions and regulation by physiological agonists and antagonists
Abdel-Malek, Z. A. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000868 · Cited by 183
Exploring “one-shot” kinetics and small molecule analysis using the ProteOn XPR36 array biosensor
Bravman, T., Bronner, V., Lavie, K., Notcovich, A., Papalia, G. A., & Myszka, D. G. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2006.08.005 · Cited by 166
Congenital Adrenal Hyperplasia
Witchel, S. F., & Azziz, R. (2011) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2010.10.001 · Cited by 161
Merke, D. P., Bornstein, S. R., Avila, N. A., & Chrousos, G. P. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-4-200202190-00012 · Cited by 147
The Tissue‐Specific Processing of Pro‐Opiomelanocortin
Bicknell, A. B. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01709.x · Cited by 135
Research works printed but not linked: 1
- New M, Lekarev O, Lin-Su K, Parsa A, Khattab A, Pina C, Yuen T, Yau M. Congenital adrenal hyperplasia. In: De Groot LJ, Beck- Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Koch C, McLachlan R, New M, Rebar R, Singer F, Vinik A, Weickert MO, eds. Endotext. South Dartmouth, MA: MDText. com; 2013. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK278953/?report=classic.
Cited by
Advances in the medical treatment of Cushing's syndrome
Feelders, R. A., Newell-Price, J., Pivonello, R., Nieman, L. K., Hofland, L. J., & Lacroix, A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30155-4 · Cited by 154
Involvement of growth factors in diabetes mellitus and its complications: A general review
Shi, G., Shi, G.-R., Zhou, J., Zhang, W., Gao, C., Jiang, Y., Zi, Z., Zhao, H., Yang, Y., & Yu, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.105 · Cited by 155
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
A clinical perspective on ectopic Cushing’s syndrome
Ragnarsson, Ó., Juhlin, C. C., Torpy, D. J., & Falhammar, H. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.12.003 · Cited by 95
An individualized approach to the management of Cushing disease
Fleseriu, M., Varlamov, E. V., Hinojosa‐Amaya, J. M., Langlois, F., & Melmed, S. K. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00868-7 · Cited by 80
A Review of Genetic Advances Related to Sex Control and Manipulation in Tilapia
Chen, J., Fan, Z., Tan, D., Jiang, D., & Wang, D. (2017) · Journal of the World Aquaculture Society · doi:10.1111/jwas.12479 · Cited by 64
Current management of Cushing's disease
Tritos, N. A., & Biller, B. M. K. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12975 · Cited by 60
Medical Management of Cushing’s Syndrome: Current and Emerging Treatments
Hinojosa‐Amaya, J. M., Ramos, D. C., & Fleseriu, M. (2019) · Drugs · doi:10.1007/s40265-019-01128-7 · Cited by 57
Tumor-Directed Therapeutic Targets in Cushing Disease
Theodoropoulou, M., & Reincke, M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02080 · Cited by 34
Novel treatments for congenital adrenal hyperplasia
Schröder, M. A. M., & der Grinten, H. L. C. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09717-w · Cited by 35
“The negative effects of ACTH could potentially be diminished by ACTH antagonists [62, 63] or ACTH receptor (MC2R) blocking [58, 64].”
BackgroundCapatina, C. A.-M., Hinojosa‐Amaya, J. M., Poiană, C., & Fleseriu, M. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1802243 · Cited by 34
CXCR1/CXCR2 antagonist G31P inhibits nephritis in a mouse model of uric acid nephropathy
Ye, Y., Zhang, Y., Wang, B., Walana, W., Wei, J., Gordon, J., & Fang, L. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.07.077 · Cited by 28
Pituitary-Directed Therapies for Cushing’s Disease
Langlois, F., Chu, J. M., & Fleseriu, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00164 · Cited by 28
“It neutralized ACTH activity in vitro and reduced GC levels in rats and in cynomolgus monkeys (112).”
BackgroundAdvances in the Medical Treatment of Cushing Disease
Tritos, N. A., & Biller, B. M. K. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.05.003 · Cited by 26
Sarafoglou, K., & Auchus, R. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae759 · Cited by 23
“Preclinical studies in rodents and cynomolgus monkeys found dose-dependent reductions in plasma corticosterone or cortisol, respectively (93, 94).”
Gehrand, A. L., Phillips, J., Malott, K., & Raff, H. (2019) · Endocrinology · doi:10.1210/en.2019-00117 · Cited by 21
“Feldhaus AL, Anderson K, Dutzar B, Ojala E,McNeill PD, Fan P, Mulligan J, Marzolf S, Karasek C, Scalley-Kim M, Stewart E, Billgren J, Rubin V, Schneider K, Jurchen D, Snow K, Barnett S, Bengtsson B, Baker B, Latham JA, Allison D, Garcia-Martinez LF. ALD1613, a novel long-acting monoclonal antibody to control ACTH-driv…”
BackgroundMethodInfluentialMedical Management of Cushing Disease
Tritos, N. A., & Biller, B. M. K. (2019) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2019.05.007 · Cited by 16
Advances in Molecular Pathophysiology and Targeted Therapy for Cushing’s Disease
Takayasu, S., Kageyama, K., & Daimon, M. (2023) · Cancers · doi:10.3390/cancers15020496 · Cited by 15
Congenital adrenal hyperplasia: New biomarkers and adult treatments
Dreves, B., Reznik, Y., & Tabarin, A. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.01.008 · Cited by 15
Update on Medical Treatment of Cushing’s Syndrome
Dillon, B. R., Agrawal, N., Schwarz, Y., Dancel-Manning, K., Tabarin, A., Lacroix, A., Hofland, L. J., & Feelders, R. A. (2025) · Drugs · doi:10.1007/s40265-025-02223-8 · Cited by 13
Identification of a novel specific small-molecule melanocortin-2-receptor antagonist
Forfar, R., Hussain, M., Khurana, P., Cook, J., Lewis, S., Popat, D., Jackson, D., McIver, E., Jerman, J. C., Taylor, D., et al. (2022) · Endocrine Connections · doi:10.1530/ec-22-0338 · Cited by 12
Monitoring treatment in pediatric patients with 21-hydroxylase deficiency
Itonaga, T., & Hasegawa, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1102741 · Cited by 11
“Managing patients with 21-OHD using glucocorticoids (GCs) is not optimal, and additional treatments have been proposed (3–5), such as the androgen antagonist, flutamide; the aromatase inhibitor, testolactone; the P450c17 inhibitor, abiraterone acetate (6, 7); the corticotropinreleasing factors, receptor 1 antagonist c…”
BackgroundHow to manage Cushing's disease after failed primary pituitary surgery
Agrawal, N., Urwyler, S. A., Mehta, S., Karavitaki, N., & Feelders, R. A. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae110 · Cited by 8
New Approaches to the Treatment of Hypercortisolism
Pofi, R., Alcubierre, D. D., Dong, J., & Tomlinson, J. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-071723-044849 · Cited by 6
The Current Treatment Landscape for Congenital Adrenal Hyperplasia
Tonge, J. J., Bacila, I. A., & Krone, N. P. (2025) · Drugs · doi:10.1007/s40265-025-02216-7 · Cited by 4
Approach to the Child and Adolescent With Adrenal Insufficiency
Patti, G., Zucconi, A., Matarese, S., Tedesco, C., Panciroli, M., Napoli, F., Iorgi, N. D., & Maghnie, M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae564 · Cited by 5
“Monoclonal antibody-based targeted therapy has been investigated in preclinical studies of ALD1613, a novel, long-acting monoclonal antibody directed toward ACTH (7, 47, 48).”
Current and Emerging Pharmacological Therapies for Cushing's Disease
Divaris, E., Kostopoulos, G., & Efstathiadou, Z. A. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128290025240216110928 · Cited by 3
Medical Therapies of Cushing’s Disease–Part 2
Schwarz, Y., Nowak, E., Halperin, R., Shah, S., Agrawal, N., & Feelders, R. A. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2025.08.003 · Cited by 2
Medical management of Cushing's disease
Kelsall, A., & Newell-Price, J. D. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819949-7.00046-9 · Cited by 3
New Trends in Treating Cushing’s Disease
Violetis, O., & Alexandraki, K. (2024) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2024.20.2.3 · Cited by 2
“48 A clinical trial examining CRN04894, an oral nonpeptide selective antagonist for ACTH acting at the MC2R, is underway (A study to evaluate the safety and PK of CRN04894 for the treatment of Cushing's syndrome; ClinicalTrials. gov identifier: NCT05804669).”
BackgroundHasegawa, Y., Itonaga, T., Ishii, T., Izawa, M., & Amano, N. (2024) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001369 · Cited by 1
Immunological, vascular and metabolic actions of androgens
Rodriguez, M. L. (2020)
Giraudot, C. (2025) · Bulletin de l Académie vétérinaire de France · doi:10.3406/bavf.2025.71138
Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia
Goai, W. H., & Torpy, D. J. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2695099
“Lu AG13909 (formerly ALD1613) is a novel high-affinity humanized neutralizing monoclonal antibody targeting ACTH, which has shown to produce dose-dependent and durable suppression of plasma cortisol and corticosterone in pre-clinical studies [73,74].”
Metadata
- Authors
- Feldhaus, A. L., Anderson, K., Dutzar, B., Ojala, E., McNeill, P. D., Fan, P., Mulligan, J., Marzolf, S., Karasek, C., Scalley-Kim, M., Stewart, E., Billgren, J., Rubin, V., Schneider, K., Jurchen, D., Snow, K., Barnett, S., Bengtsson, B., Baker, B., Latham, J. A., Allison, D., & Garcia-Martinez, L. F.
- Affiliations
- Alder (United States) (US)
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2016-12
- Volume
- 158
- Issue
- 1
- Pages
- en.2016-1455
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2558818096
- Cited by
- 32
- References
- 28
- Citations by year
- 2025: 3 · 2024: 7 · 2023: 5 · 2022: 3 · 2021: 1 · 2020: 3 · 2019: 4 · 2018: 5 · 2017: 1
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- ACTH, neutralizing monoclonal antibodies, melanocortin receptors, corticosterone, cortisol, congenital adrenal hyperplasia, Cushing's disease, restraint stress, non-human primates, glucocorticoid regulation
- MeSH terms
- Adrenal Hyperplasia, Congenital, Adrenocorticotropic Hormone, Animals, Antibodies, Monoclonal, Corticosterone, Cricetulus, Drug Evaluation, Preclinical, Cricetinae, Humans, Hydrocortisone, Macaca fascicularis, Male, Rabbits, Rats, Inbred Lew, Stress, Psychological, CHO Cells, Receptor, Melanocortin, Type 2, Pituitary ACTH Hypersecretion, Rats, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.